Analyst Ratings For Allergan plc (NYSE:AGN)
Today, Mizuho reiterated its Buy rating on Allergan plc (NYSE:AGN) with a price target of $171.00.
There are 11 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Allergan plc (NYSE:AGN) is Hold with a consensus target price of $173.1553 per share, a potential 33.64% upside.
Some recent analyst ratings include
- 6/25/2019-Allergan plc (NYSE:AGN) had its Buy rating reiterated by Mizuho with a $171.00 price target
- 6/11/2019-Allergan plc (NYSE:AGN) has coverage initiated with a Underweight ➝ Underweight rating and $133.00 price target
- 6/10/2019-Allergan plc (NYSE:AGN) had its Buy rating reiterated by Wells Fargo & Co
- 5/28/2019-Allergan plc (NYSE:AGN) has coverage initiated with a Neutral ➝ Neutral rating and $154.00 price target
- On 3/7/2019 Brent L Saunders, Chairman, bought 1,760 with an average share price of $143.67 per share and the total transaction amounting to $252,859.20.
- On 11/16/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $157.00 per share and the total transaction amounting to $157,000.00.
- On 9/6/2018 Christopher J. Coughlin, Director, bought 10,000 with an average share price of $190.64 per share and the total transaction amounting to $1,906,400.00.
- On 8/30/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $190.59 per share and the total transaction amounting to $171,531.00.
- On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
- On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
- On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.
About Allergan plc (NYSE:AGN)
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. Read More…
Recent Trading Activity for Allergan plc (NYSE:AGN)
Shares of Allergan plc closed the previous trading session at 129.57 −1.34 1.02% with 130.67 shares trading hands.